The cost-effectiveness of preventing cytomegalovirus disease in AIDS patients

被引:5
作者
Paltiel, AD
Freedberg, KA
机构
[1] Yale Univ, Sch Med, New Haven, CT 06520 USA
[2] Boston Univ, Sch Med, Clin Econ Res Unit, Sect Gen Internal Med,Dept Med, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, Thorndike Mem Lab, Boston Med Ctr, Boston, MA 02118 USA
关键词
health care; cost analysis;
D O I
10.1287/inte.28.3.34
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
To examine the costs and consequences of prophylaxis against cytomegalovirus (CMV) infection, we developed a compartmental model of the natural history of late-stage HIV disease. We used data on the progression of illness, economic costs, the incidence of infections, the efficacy and toxicity of therapy, and patient quality of life from national cohort studies, randomized clinical trials, and resource-utilization surveys. We found that CMV prophylaxis confers additional quality-adjusted life-years at a lower-bound, marginal cost of $160,000. While this cost-effectiveness result compares unfavorably with alternative uses of scarce resources, it is sensitive to assumptions regarding the price of therapy and the incidence of infection.
引用
收藏
页码:34 / 51
页数:18
相关论文
共 63 条
[1]   PRELIMINARY-ANALYSIS OF THE CONCORDE TRIAL [J].
ABOULKER, JP ;
SWART, AM .
LANCET, 1993, 341 (8849) :889-890
[2]  
[Anonymous], 1995, MMWR Recomm Rep, V44, P1
[3]   ECONOMIC AND POLICY IMPLICATIONS OF EARLY INTERVENTION IN HIV DISEASE [J].
ARNO, PS ;
SHENSON, D ;
SIEGEL, NF ;
FRANKS, P ;
LEE, PR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (11) :1493-1498
[4]  
BALFOUR HH, 1990, REV INFECT DIS, V12, pS849
[5]  
BROSGART C, 1996, 11 INT C AIDS VANC C
[6]   Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02) :146-154
[7]   COST AND BENEFIT OF SECONDARY PROPHYLAXIS FOR PNEUMOCYSTIS-CARINII PNEUMONIA [J].
CASTELLANO, AR ;
NETTLEMAN, MD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (06) :820-824
[8]   COST-EFFECTIVENESS LEAGUE TABLES - MORE HARM THAN GOOD [J].
DRUMMOND, M ;
TORRANCE, G ;
MASON, J .
SOCIAL SCIENCE & MEDICINE, 1993, 37 (01) :33-40
[9]   Survival from early, intermediate, and late stages of HIV infection [J].
Enger, C ;
Graham, N ;
Peng, Y ;
Chmiel, JS ;
Kingsley, LA ;
Detels, R ;
Munoz, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (17) :1329-1334
[10]   THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
HANSEN, N ;
COLLIER, AC ;
CAREY, JT ;
PARA, MF ;
HARDY, WD ;
DOLIN, R ;
POWDERLY, WG ;
ALLAN, JD ;
WONG, B ;
MERIGAN, TC ;
MCAULIFFE, VJ ;
HYSLOP, NE ;
RHAME, FS ;
BALFOUR, HH ;
SPECTOR, SA ;
VOLBERDING, P ;
PETTINELLI, C ;
ANDERSON, J .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) :727-737